Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions

Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.